NL-OMON26753RecruitingNot Applicable
The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritis.
Department of Rheumatology, University Medical Centre Sint Radboud0 sites132 target enrollmentStarted: TBDLast updated:
Conditions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 132
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •1. RA diagnosis according to ACR criteria;
- •2. Having been treated adequately with one of the anti-TNF alpha agents with insufficient effects;
Exclusion Criteria
- •1. Former treatment with abatacept or rituximab;
- •2. Patient's or physician's preference for one of the agents;
Investigators
Similar Trials
Not yet recruiting
Not Applicable
The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid arthritisrheumatoid arthritisNL-OMON32522niversitair Medisch Centrum Sint Radboud261
Active, not recruiting
Not Applicable
The cost-effectiveness of abatacept, rituximab or anti-TNF alpha for patients with rheumatoid artritis. - Dutch Rheumatoid Arthritis Monitoring (DREAM) Targetted Immune Modulator Evaluation (TIME)MedDRA version: 12.0Level: PTClassification code 10039073Term: Rheumatoid arthritisRheumatoid arthritisEUCTR2008-005450-20-BERadboud University Nijmegen Medical Centre, department of Rheumatic Diseases261
Completed
Not Applicable
A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and CancerThromboembolismNCT05643885Pfizer7,304
Active, not recruiting
Phase 1
Comparison of two treatments rituximab in patients with autoimmune disease resistant to conventional treatmentsEUCTR2011-005856-32-ESFundación Progreso y Salud9
Completed
Unknown
Cost-effectiveness study of atezolizumab vs. durvalumab : real-world data on first-line chemotherapy combined with immune-checkpoint inhibitors for extensive disease small-cell lung cancerextensive disease small cell lung cancerJPRN-UMIN000053483Kobe Minimally Invasive Cancer Center200